Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Anaptys Announces Participation in November and December Investor Conferences

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference

Anaptys Announces Participation in November Investor Conferences

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25